Heart check for new Weight-Loss drug: survodutide under scrutiny

NCT ID NCT06200467

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study checks whether survodutide, a new weight-loss injection, affects heart rhythm in 110 overweight or obese adults. Participants receive survodutide or placebo for about 30 weeks, with heart tests before and after. The goal is to see if the drug is safe for the heart, not to measure weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: survodutide (BI 456906)
What this could lead to: If it works, this could help ensure that survodutide is safe for the heart, supporting its development as a weight-loss treatment.
What could go wrong: This is an early Phase 1 safety study, not designed to prove weight loss. The results may not predict real-world outcomes, and heart effects are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

CRS Clinical Research Services Mannheim GmbH

Mannheim, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.